Mathematical modeling in tobacco control research: Initial Results From a Systematic Review

Nicotine and Tobacco Research

Volumn 18, Issue 3, 2016, Pages 229-242

  Feirman, Shari P ^a,b   Donaldson, Elisabeth ^a,b   Glasser, Allison M ^a   Pearson, Jennifer L ^a,b   Niaura, Ray ^a,b,c   Rose, Shyanika W ^a   Abrams, David B ^a,b,c   Villanti, Andrea C ^a,b  

^a Schroeder Institute for Tobacco Research and Policy Studies   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT SMOKING; ECONOMIC ASPECT; HUMAN; INCIDENCE; MASS MEDIUM; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING BAN; SMOKING CESSATION; SMOKING REGULATION; SYSTEMATIC REVIEW; TAX; TOBACCO USE; DECISION MAKING; FOOD AND DRUG ADMINISTRATION; MEDICAL RESEARCH; PREVENTION AND CONTROL; PROCEDURES; SMOKING; THEORETICAL MODEL; TOBACCO USE DISORDER; TRENDS; UNITED STATES;

BIOMEDICAL RESEARCH; DECISION MAKING; HUMANS; MODELS, THEORETICAL; SMOKING; TOBACCO USE DISORDER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84962911434     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv104     Document Type: Review

References (276)

1. Wang H, Preston SH. Forecasting United States mortality using cohort smoking histories. Proc Natl Acad Sci USA. 2009;106(2):393-398. doi:10.1073/pnas.0811809106.
2. Basu S, Stuckler D, Bitton A, Glantz SA. Projected effects of tobacco smoking on worldwide tuberculosis control: mathematical modelling analysis. BMJ. 2011;343:d5506. doi:10.1136/bmj.d5506.
3. Didkowska J, Wojciechowska U, Koskinen HL, Tavilla A, Dyba T, Hakulinen T. Future lung cancer incidence in Poland and Finland based on forecasts on hypothetical changes in smoking habits. Acta Oncol. 2011;50(1):81-87. doi:10.3109/0284186X.2010.488247.
4. Ahmad S, Billimek J. Limiting youth access to tobacco: comparing the long-term health impacts of increasing cigarette excise taxes and raising the legal smoking age to 21 in the United States. Health Policy. 2007;80(3):378-391. doi:10.1016/j.healthpol.2006.04.001.
5. Soerjomataram I, de Vries E, Engholm G, et al. Impact of a smoking and alcohol intervention programme on lung and breast cancer incidence in Denmark: an example of dynamic modelling with Prevent. Eur J Cancer. 2010;46(14):2617-2624. doi:10.1016/j.ejca.2010.07.051.
6. Guerrero F, Santonja FJ, Villanueva RJ. Analysing the Spanish smoke-free legislation of 2006: a new method to quantify its impact using a dynamic model. Int J Drug Policy. 2011;22(4):247-251. doi:10.1016/j.drugpo.2011.05.003.
7. Levy D, Gallus S, Blackman K, Carreras G, La Vecchia C, Gorini G. Italy SimSmoke: the effect of tobacco control policies on smoking prevalence and smoking attributable deaths in Italy. BMC Public Health. 2012;12(1):709. doi:10.1186/1471-2458-12-709.
8. Mabry PL, Marcus SE, Clark PI, Leischow SJ, Méndez D. Systems science: a revolution in public health policy research. Am J Public Health. 2010;100(7):1161-1163. doi:10.2105/AJPH.2010.198176.
9. Food and Drug Administration. Center for Tobacco Products: Research Priorities. 2013. www.fda.gov/downloads/TobaccoProducts/NewsEvents/UCM382852.pdf. Accessed August 7, 2014.
10. Food and Drug Administration. Center for Tobacco Products. A Public Workshop-Modeling and Statistical Methods for the Regulatory Assessment of Tobacco Products. 2014. www.fda.gov/TobaccoProducts/NewsEvents/ucm372587.htm. Accessed January 14, 2015.
11. U.S. Department of Health and Human Services. "Appendix 15.1: Tobacco Control Simulation Models." Atlanta, GA: The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General; 2014. www.surgeongeneral.gov/library/reports/50-years-of-progress/sgr50-chap-15-appendix.pdf. Accessed April 2, 2015.
12. Kahende JW, Loomis BR, Adhikari B, Marshall L. A review of economic evaluations of tobacco control programs. Int J Environ Res Public Health. 2009;6(1):51-68. doi:10.3390/ijerph6010051.
13. Tobacco Products Scientific Advisory Committee. Menthol Cigarettes and Public Health: Review of the Scientific Evidence and Recommendations. 2011. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisoryCommittee/UCM269697.pdf. Accessed April 2, 2015.
14. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295-1310. doi:10.1002/hec.1148.
15. Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667-677. doi:10.1177/027 2989X12454577.
16. Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol-realist and meta-narrative evidence synthesis: evolving standards (RAMESES). BMC Med Res Methodol. 2011;11(1):115. doi:10.1186/1471-2288-11-115.
17. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. www.cochrane-handbook.org. Accessed May 22, 2015.
18. Feirman S, Donaldson EA, Pearson JL, et al. Mathematical modeling in tobacco control research: protocol for a systematic review. BMJ Open. 2015;5(4):e007269. doi:10.1136/bmjopen-2014-007269.
19. Capannesi M, Boshuizen HC, Willemsen MC, van Houwelingen HC. How to obtain long term projections for smoking behaviour: a case study in the Dutch population. Comput Math Methods Med. 2009;10(2):155-164. doi:10.1080/17486700802260101.
20. Carreras G, Gorini G, Gallus S, Iannucci L, Levy DT. Predicting the future prevalence of cigarette smoking in Italy over the next three decades. Eur J Public Health. 2012;22(5):699-704. doi:10.1093/eurpub/ckr108.
21. Gartner CE, Barendregt JJ, Hall WD. Predicting the future prevalence of cigarette smoking in Australia: how low can we go and by when? Tob Control. 2009;18(3):183-189. doi:10.1136/tc.2008.027615.
22. Kemm J. A model to predict the results of changes in smoking behaviour on smoking prevalence. J Public Health Med. 2003;25(4):318-324. www.ncbi.nlm.nih.gov/pubmed/14747591. Accessed February 24, 2015.
23. Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB. Exploring scenarios to dramatically reduce smoking prevalence: a simulation model of the three-part cessation process. Am J Public Health. 2010;100(7):1253-1259. doi:10.2105/AJPH.2009.166785.
24. Mendez D, Warner KE. Smoking prevalence in 2010: why the healthy people goal is unattainable. Am J Public Health. 2000;90(3):401-403. www.ncbi.nlm.nih.gov/pubmed/10705858. Accessed February 24, 2015.
25. Mendez D, Warner KE. Adult cigarette smoking prevalence: declining as expected (not as desired). Am J Public Health. 2004;94(2):251-252. www.ncbi.nlm.nih.gov/pubmed/14759934. Accessed February 24, 2015.
26. Mendez D, Warner KE, Courant PN. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. Am J Epidemiol. 1998;148(3):249-258. www.ncbi.nlm.nih.gov/pubmed/9690361. Accessed February 24, 2015.
27. Pechmann C, Dixon P, Layne N. An assessment of US and Canadian smoking reduction objectives for the year 2000. Am J Public Health. 1998;88(9):1362-1367. www.ncbi.nlm.nih.gov/pubmed/9736877. Accessed February 24, 2015.
28. Pierce JP, Fiore MC, Novotny TE, Hatziandreu EJ, Davis RM. Trends in cigarette smoking in the United States. Projections to the year 2000. JAMA. 1989;261(1):61-65. www.ncbi.nlm.nih.gov/pubmed/2908996. Accessed February 24, 2015.
29. Smith DM, Pearce JR, Harland K. Can a deterministic spatial microsimulation model provide reliable small-area estimates of health behaviours? An example of smoking prevalence in New Zealand. Health Place. 2011;17(2):618-624. doi:10.1016/j.healthplace.2011.01.001.
30. Warner KE, Mendez D. Tobacco control policy in developed countries: yesterday, today, and tomorrow. Nicotine Tob Res. 2010;12(9):876-887. doi:10.1093/ntr/ntq125.
31. Warner KE, Méndez D. Accuracy and importance of projections from a dynamic simulation model of smoking prevalence in the United States. Am J Public Health. 2012;102(11):2045-2048. doi:10.2105/AJPH.2012.300771.
32. Centers for Disease Control and Prevention (CDC). Projected smokingrelated deaths among youth-United States. MMWR Morb Mortal Wkly Rep. 1996;45(44):971-974. www.ncbi.nlm.nih.gov/pubmed/8965796. Accessed February 24, 2015.
33. Akushevich I, Kravchenko JS, Manton KG. Health-based population forecasting: effects of smoking on mortality and fertility. Risk Anal. 2007;27(2):467-482. doi:10.1111/j.1539-6924.2007.00898.x.
34. Blakely T, Carter K, Wilson N, et al. If nobody smoked tobacco in New Zealand from 2020 onwards, what effect would this have on ethnic inequalities in life expectancy? N Z Med J. 2010;123(1320):26-36. www.ncbi.nlm.nih.gov/pubmed/20720600. Accessed February 24, 2015.
35. Brennan P, Bray I. Recent trends and future directions for lung cancer mortality in Europe. Br J Cancer. 2002;87(1):43-48. doi:10.1038/sj.bjc.6600352.
36. Brown CC, Kessler LG. Projections of lung cancer mortality in the United States: 1985-2025. J Natl Cancer Inst. 1988;80:43-51. http://jnci.oxfordjournals.org/content/80/1/43.short. Accessed February 24, 2015.
37. Critchley JA, Capewell S. Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels. J Epidemiol Community Health. 2003;57(4):243-247. www.ncbi.nlm.nih.gov/pubmed/12646537. Accessed February 24, 2015.
38. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Ruttenvan Mölken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164(4):590-596. doi:10.1164/ajrccm.164.4.2003167.
39. Gavin AT, O'Reilly D. Cancer in Northern Ireland by 2002. Ulster Med J. 1996;65(2):106-112. www.ncbi.nlm.nih.gov/pubmed/8979775. Accessed February 24, 2015.
40. Hakulinen T, Pukkala E. Future incidence of lung cancer: forecasts based on hypothetical changes in the smoking habits of males. Int J Epidemiol. 1981;10(3):233-240. www.ncbi.nlm.nih.gov/pubmed/7287283. Accessed February 24, 2015.
41. Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT. Chapter 5: actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation. Risk Anal. 2012;32(Suppl 1):S51-S68. doi:10.1111/j.1539-6924.2011.01775.x.
42. Lightwood JM, Coxson PG, Bibbins-Domingo K, Williams LW, Goldman L. Coronary heart disease attributable to passive smoking: CHD Policy Model. Am J Prev Med. 2009;36(1):13-20. doi:10.1016/j. amepre.2008.09.030.
43. Mao Y, Gibbons L, Wong T. A model to predict the results of changes in smoking behaviour on smoking prevalence. J Public Health Med. 2003;25(4):318-324. www.ncbi.nlm.nih.gov/pubmed/14747591. Accessed February 24, 2015.
44. Menvielle G, Soerjomataram I, de Vries E, et al. Scenarios of future lung cancer incidence by educational level: modelling study in Denmark. Eur J Cancer. 2010;46(14):2625-2632. doi:10.1016/j.ejca.2010.07.027.
45. Mulder I, Hoogenveen RT, Smit HA, Bueno de Mesquita HB. Modelling future mortality reduction through smoking cessation in the European Union. Eur J Public Health. 2004;14(1):79-85. www.ncbi.nlm.nih.gov/pubmed/15080397. Accessed February 24, 2015.
46. Mulder I, Hoogenveen RT, van Genugten ML, et al. Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. Eur J Gastroenterol Hepatol. 2002;14(12):1343-1353. www.ncbi.nlm.nih.gov/pubmed/12468956. Accessed February 24, 2015.
47. Mulder I, van Genugten ML, Hoogenveen RT, de Hollander AE, Buenode-Mesquita HB. The impact of smoking on future pancreatic cancer: a computer simulation. Ann Oncol. 1999;10(Suppl 4):74-78. www.ncbi.nlm.nih.gov/pubmed/10436790. Accessed February 24, 2015.
48. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504. doi:10.1016/S0140-6736(96)07492-2.
49. Nam CB, Rogers RG, Hummer RA. Impact of future cigarette smoking scenarios on mortality of the adult population in the United States,2000-2050. Soc Biol. 1996;43(3-4):155-168. www.ncbi.nlm.nih.gov/pubmed/9204694. Accessed February 24, 2015.
50. Neovius K, Rasmussen F, Sundström J, Neovius M. Forecast of future premature mortality as a result of trends in obesity and smoking: nationwide cohort simulation study. Eur J Epidemiol. 2010;25(10):703-709. doi:10.1007/s10654-010-9485-x.
51. Pierce JP, Thurmond L, Rosbrook B. Projecting international lung cancer mortality rates: first approximations with tobacco-consumption data. J Natl Cancer Inst Monogr. 1992(12):45-49. www.ncbi.nlm.nih.gov/pubmed/1616809. Accessed February 24, 2015.
52. Russell LB, Carson JL, Taylor WC, Milan E, Dey A, Jagannathan R. Modeling all-cause mortality: projections of the impact of smoking cessation based on the NHEFS. NHANES I Epidemiologic Follow-up Study. Am J Public Health. 1998;88(4):630-636. www.ncbi.nlm.nih.gov/pubmed/9551006 Accessed February 24, 2015.
53. Shibuya K, Inoue M, Lopez AD. Statistical modeling and projections of lung cancer mortality in 4 industrialized countries. Int J Cancer. 2005;117(3):476-485. doi:10.1002/ijc.21078.
54. Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med. 2009;361(23):2252-2260. doi:10.1056/NEJMsa0900459.
55. Strong K, Mathers C, Epping-Jordan J, ResnikoffS, Ullrich A. Preventing cancer through tobacco and infection control: how many lives can we save in the next 10 years? Eur J Cancer Prev. 2008;17(2):153-161. doi:10.1097/CEJ.0b013e3282b6fda8.
56. Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Modeling the future burden of stroke in The Netherlands: impact of aging, smoking, and hypertension. Stroke. 2005;36(8):1648-1655. doi:10.1161/01.STR.0000173221.37568.d2.
57. Sumner W II. Estimating the health consequences of replacing cigarettes with nicotine inhalers. Tob Control. 2003;12(2):124-132. www.ncbi.nlm.nih.gov/pubmed/12773720. Accessed February 24, 2015.
58. Tengs TO, Osgood ND, Lin TH. Public health impact of changes in smoking behavior: results from the Tobacco Policy Model. Med Care. 2001;39(10):1131-1141. www.ncbi.nlm.nih.gov/pubmed/11567175. Accessed February 24, 2015.
59. van Meijgaard J, Fielding JE. Estimating benefits of past, current, and future reductions in smoking rates using a comprehensive model with competing causes of death. Prev Chronic Dis. 2012;9:E122. www.ncbi.nlm.nih.gov/pubmed/22765931. Accessed February 24, 2015.
60. Wen CP, Tsai SP, Chen CJ, Cheng TY, Tsai MC, Levy DT. Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios. Tob Control. 2005;14(Suppl 1):i76-80. doi:10.1136/tc.2004.007955.
61. Yeh JM, Hur C, Schrag D, et al. Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med. 2013;10(5):e1001451. doi:10.1371/journal.pmed.1001451.
62. Arredondo A, Carrillo C, Zuniga A. Economic burden of expected epidemiological changes in diseases related to tobacco, Mexico. Rev Saude Publica. 2007;41(4):523-529. www.ncbi.nlm.nih.gov/pubmed/17589749. Accessed February 24, 2015.
63. Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One. 2011;6(9):e24870. doi:10.1371/journal.pone.0024870.
64. Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N Engl J Med. 1997;337(15):1052-1057. doi:10.1056/NEJM199710093371506.
65. Bolin K, Borgman B, Gip C, Wilson K. Current and future avoidable cost of smoking-estimates for Sweden 2007. Health Policy. 2011;103(1):83-91. doi:10.1016/j.healthpol.2011.08.011.
66. De Smedt D, Kotseva K, De Bacquer D, et al. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. Eur Heart J. 2012;33(22):2865-2872. doi:10.1093/eurheartj/ehs210.
67. Goldman D, Michaud PC, Lakdawalla D, Zheng Y, Gailey A, Vaynman I. The fiscal consequences of trends in population health. Natl Tax J. 2010;63(2):307-330. http://lawweb.usc.edu/assets/docs/contribute/FiscalConsequencesofPopHealthTrends-v1.pdf. Accessed February 24, 2015.
68. Goldman DP, Zheng Y, Girosi F, et al. The benefits of risk factor prevention in Americans aged 51 years and older. Am J Public Health. 2009;99(11):2096-2101. doi:10.2105/AJPH.2009.172627.
69. Hurley SF, Matthews JP. The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost EffResour Alloc. 2007;5:2. doi:10.1186/1478-7547-5-2.
70. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of smoking cessation to prevent age-related macular degeneration. Cost EffResour Alloc. 2008;6:18. doi:10.1186/1478-7547-6-18.
71. Magnus A, Cadilhac D, Sheppard L, Cumming T, Pearce D, Carter R. Economic benefits of achieving realistic smoking cessation targets in Australia. Am J Public Health. 2011;101(2):321-327. doi:10.2105/AJPH.2009.191056.
72. Naidoo B, Stevens W, McPherson K. Modelling the short term consequences of smoking cessation in England on the hospitalisation rates for acute myocardial infarction and stroke. Tob Control. 2000;9(4):397-400. www.ncbi.nlm.nih.gov/pubmed/11106709. Accessed February 24, 2015.
73. Yang W, Dall TM, Zhang Y, et al. Simulation of quitting smoking in the military shows higher lifetime medical spending more than offset by productivity gains. Health Aff(Millwood). 2012;31(12):2717-2726. doi:10.1377/hlthaff.2010.1048.
74. Levy DT, Cummings KM, Hyland A. A simulation of the effects of youth initiation policies on overall cigarette use. Am J Public Health. 2000;90(8):1311-1314. www.ncbi.nlm.nih.gov/pubmed/10937017. Accessed February 24, 2015.
75. Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB. Reaching Healthy People 2010 by 2013: a SimSmoke simulation. Am J Prev Med. 2010;38(Suppl 3):S373-381. doi:10.1016/j.amepre.2009.11.018.
76. Levy DT, Nikolayev L, Mumford E. Recent trends in smoking and the role of public policies: results from the SimSmoke tobacco control policy simulation model. Addiction. 2005;100(10):1526-1536. doi:10.1111/j.1360-0443.2005.01205.x.
77. Levy DT, Nikolayev L, Mumford E, Compton C. The Healthy People 2010 smoking prevalence and tobacco control objectives: results from the SimSmoke tobacco control policy simulation model (United States). Cancer Causes Control. 2005;16(4):359-371. doi:10.1007/s10552-004-7841-4.
78. Stoforos C, Mergos G. Modelling EU tobacco policy reform. Appl Econ. 2004;36:2167-2175.
79. Taylor DC, Chu P, Rosen VM, Baker CL, Thompson D. Budgetary impact of varenicline in smoking cessation in the United Kingdom. Value Health. 2009;12(1):28-33. doi:10.1111/j.1524-4733.2008.00395.x.
80. van Walbeek C. A simulation model to predict the fiscal and public health impact of a change in cigarette excise taxes. Tob Control. 2010;19(1):31-36. doi:10.1136/tc.2008.028779.
81. Ahmad S, Billimek J. Estimating the health impacts of tobacco harm reduction policies: a simulation modeling approach. Risk Anal. 2005;25(4):801-812. doi:10.1111/j.1539-6924.2005.00647.x.
82. Apelberg BJ, Onicescu G, Avila-Tang E, Samet JM. Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States. Am J Public Health. 2010;100(2):341-348. doi:10.2105/AJPH.2008.147223.
83. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370(9604):2044-2053. doi:10.1016/S0140-6736(07)61698-5.
84. Avila-Tang E, Apelberg BJ, Yamaguchi N, Katanoda K, Sobue T, Samet JM. Modelling the health benefits of smoking cessation in Japan. Tob Control. 2009;18(1):10-17. doi:10.1136/tc.2007.024620.
85. Bauer P, Barthelmes D, Kurz M, Fleischhauer JC, Sutter FK. The potential effect of population development, smoking and antioxidant supplementation on the future epidemiology of age-related macular degeneration inSwitzerland. Klin Monbl Augenheilkd. 2008;225(5):376-379. doi:10.105 5/s-2008-1027264.
86. Bemelmans WJ, van Lenthe F, Hoogenveen R, et al. Modeling predicted that tobacco control policies targeted at lower educated will reduce the differences in life expectancy. J Clin Epidemiol. 2006;59(9):1002-1008. doi:10.1016/j.jclinepi.2006.02.008.
87. Carreras G, Gorini G, Paci E. Can a national lung cancer screening program in combination with smoking cessation policies cause an early decrease in tobacco deaths in Italy? Cancer Prev Res (Phila). 2012;5(6):874-882. doi:10.1158/1940-6207.CAPR-12-0019.
88. Currie LM, Blackman K, Clancy L, Levy DT. The effect of tobacco control policies on smoking prevalence and smoking-attributable deaths in Ireland using the IrelandSS simulation model. Tob Control. 2013;22(e1):e25-e32. doi:10.1136/tobaccocontrol-2011-050248.
89. Cutler DM, Gruber J, Hartman RS, Landrum MB, Newhouse JP, Rosenthal MB. The economic impacts of the tobacco settlement. J Policy Anal Manage. 2002;21(1):1-19. doi:10.1002/pam.1037.
90. Emery S, Ake CF, Navarro AM, Kaplan RM. Simulated effect of tobacco tax variation on Latino health in California. Am J Prev Med. 2001;21(4):278-283. www.ncbi.nlm.nih.gov/pubmed/11701298. Accessed February 24, 2015.
91. Ferrante D, Levy D, Peruga A, Compton C, Romano E. The role of public policies in reducing smoking prevalence and deaths: the Argentina Tobacco Policy Simulation Model. Rev Panam Salud Publica. 2007;21(1):37-49. www.ncbi.nlm.nih.gov/pubmed/17439692. Accessed February 24, 2015.
92. Gray B, Schuetz CA, Weng W, Peskin B, Rosner B, Lipner RS. Physicians' actions and influence, such as aggressive blood pressure control, greatly improve the health of diabetes patients. Health Aff(Millwood). 2012;31(1):140-149. doi:10.1377/hlthaff.2011.0895.
93. Kaplan RM, Ake CF, Emery SL, Navarro AM. Simulated effect of tobacco tax variation on population health in California. Am J Public Health. 2001;91(2):239-244. www.ncbi.nlm.nih.gov/pubmed/11211632. Accessed February 24. 2015.
94. Katanoda K, Levy DT, Nakamura M, Hagimoto A, Oshima A. Modeling the effect of disseminating brief intervention for smoking cessation at medical facilities in Japan: a simulation study. Cancer Causes Control. 2012;23(6):929-939. doi:10.1007/s10552-012-9964-3.
95. Kawachi I, Purdie G. Should treatment of mild to moderate hypertension be targeted? Results from a Markov cohort model incorporating multiple risk factors. J Hum Hypertens. 1990;4(6):651-658. www.ncbi.nlm.nih.gov/pubmed/2151391. Accessed February 24, 2015.
96. Konfino J, Ferrante D, Mejia R, et al. Impact on cardiovascular disease events of the implementation of Argentina's national tobacco control law. Tob Control. 2014;23(2):e6. doi:10.1136/tobaccocontrol-2012-050599.
97. Lawrence WF, Smith SS, Baker TB, Fiore MC. Does over-thecounter nicotine replacement therapy improve smokers' life expectancy? Tob Control. 1998;7(4):364-368. www.ncbi.nlm.nih.gov/pubmed/10093169. Accessed February 24, 2015.
98. Levy DT, Bales S, Lam NT, Nikolayev L. The role of public policies in reducing smoking and deaths caused by smoking in Vietnam: results from the Vietnam tobacco policy simulation model. Soc Sci Med. 2006;62(7):1819-1830. doi:10.1016/j.socscimed.2005.08.043.
99. Levy DT, Benjakul S, Ross H, Ritthiphakdee B. The role of tobacco control policies in reducing smoking and deaths in a middle income nation: results from the Thailand SimSmoke simulation model. Tob Control. 2008;17(1):53-59. doi:10.1136/tc.2007.022319.
100. Levy DT, Blackman K, Currie LM, Levy J, Clancy L. SimSmokeFinn: how far can tobacco control policies move Finland toward tobaccofree 2040 goals? Scand J Public Health. 2012;40(6):544-552. doi:10.1177/1403494812456635.
101. Levy DT, Blackman K, Currie LM, Mons U. Germany SimSmoke: the effect of tobacco control policies on future smoking prevalence and smoking-attributable deaths in Germany. Nicotine Tob Res. 2013;15(2):465-473. doi:10.1093/ntr/nts158.
102. Levy DT, Boyle RG, Abrams DB. The role of public policies in reducing smoking: the Minnesota SimSmoke tobacco policy model. Am J Prev Med. 2012;43:S179-S186. doi:10.1016/j.amepre.2012.07.037.
103. Levy DT, Cho SI, Kim YM, Park S, Suh MK, Kam S. SimSmoke model evaluation of the effect of tobacco control policies in Korea: the unknown success story. Am J Public Health. 2010;100(7):1267-1273. doi:10.2105/AJPH.2009.166900.
104. Levy DT, Cummings KM, Hyland A. Increasing taxes as a strategy to reduce cigarette use and deaths: results of a simulation model. Prev Med. 2000;31(3):279-286. doi:10.1006/pmed.2000.0696.
105. Levy DT, Currie L, Clancy L. Tobacco control policy in the UK: blueprint for the rest of Europe? Eur J Public Health. 2013;23(2):201-206. doi:10.1093/eurpub/cks090.
106. Levy DT, Friend K. A computer simulation model of mass media interventions directed at tobacco use. Prev Med. 2001;32(3):284-294. doi:10.1006/pmed.2000.0808.
107. Levy DT, Friend K. Examining the effects of tobacco treatment policies on smoking rates and smoking related deaths using the SimSmoke computer simulation model. Tob Control. 2002;11(1):47-54. www.ncbi.nlm.nih.gov/pubmed/11891368. Accessed February 24, 2015.
108. Levy DT, Friend K, Holder H, Carmona M. Effect of policies directed at youth access to smoking: results from the SimSmoke computer simulation model. Tob Control. 2001;10(2):108-116. www.ncbi.nlm.nih.gov/pubmed/11387530. Accessed February 24, 2015.
109. Levy DT, Friend K, Polishchuk E. Effect of clean indoor air laws on smokers: the clean air module of the SimSmoke computer simulation model. Tob Control. 2001;10(4):345-351. www.ncbi.nlm.nih.gov/pubmed/11740026 Accessed February 24, 2015.
110. Levy DT, Mumford EA, Pesin B. Tobacco control policies and reductions in smoking rates and smoking-related deaths. Expert Rev Pharmacoecon Outcomes Res. 2003;3(4):457-468. doi:10.1586/14737167.3.4.457.
111. Levy DT, Pearson JL, Villanti AC, et al. Modeling the future effects of a menthol ban on smoking prevalence and smoking-attributable deaths in the United States. Am J Public Health. 2011;101(7):1236-1240. doi:10.2105/AJPH.2011.300179.
112. Levy DT, Ross H, Powell L, Bauer JE, Lee HR. The role of public policies in reducing smoking prevalence and deaths caused by smoking in Arizona: results from the Arizona tobacco policy simulation model. J Public Health Manag Pract. 2007;13(1):59-67. www.ncbi.nlm.nih.gov/pubmed/17149101. Accessed February 24, 2015.
113. Levy DT, Ross H, Zaloshnja E, Shuperka R, Rusta M. The role of tobacco control policies in reducing smoking and deaths caused by smoking in an Eastern European nation: results from the Albania SimSmoke simulation model. Cent Eur J Public Health. 2008;16(4):189-198. www.ncbi.nlm.nih.gov/pubmed/19256288. Accessed February 24, 2015.
114. Levy DT, Tworek C, Hahn EJ, Davis RE. The Kentucky SimSmoke tobacco policy simulation model: reaching Healthy People 2010 goals through policy change. South Med J. 2008;101(5):503-507. doi:10.1097/SMJ.0b013e31816c013c.
115. Levy DT, Wen CP, Chen TY, Oblak M. Increasing taxes to reduce smoking prevalence and smoking attributable mortality in Taiwan: results from a tobacco policy simulation model. Tob Control. 2005;14(Suppl 1):i45-50. doi:10.1136/tc.2003.005660.
116. McMahon PM, Kong CY, Johnson BE, et al. Chapter 9: the MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal. 2012;32(Suppl 1):S117-S124. doi:10.1111/j.1539-6924.2011.01652.x.
117. McMahon PM, Kong CY, Weinstein MC, et al. Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer. 2008;113(12):3440-3449. doi:10.1002/cncr.23962.
118. Mejia AB, Ling PM, Glantz SA. Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob Control. 2010;19(4):297-305. doi:10.1136/tc.2009.031427.
119. Nagelhout GE, Levy DT, Blackman K, Currie L, Clancy L, Willemsen MC. The effect of tobacco control policies on smoking prevalence and smoking-attributable deaths. Findings from the Netherlands SimSmokeTobacco Control Policy Simulation Model. Addiction. 2012;107(2):407-416. doi:10.1111/j.1360-0443.2011.03642.x.
120. Rivara FP, Ebel BE, Garrison MM, Christakis DA, Wiehe SE, Levy DT. Prevention of smoking-related deaths in the United States. Am J Prev Med. 2004;27(2):118-125. doi:10.1016/j.amepre.2004.04.014.
121. Soerjomataram I, Barendregt JJ, Gartner C, Kunst A, Møller H, Avendano M. Reducing inequalities in lung cancer incidence through smoking policies. Lung Cancer. 2011;73(3):268-273. doi:10.1016/j. lungcan.2011.01.009.
122. Tengs TO, Ahmad S, Moore R, Gage E. Federal policy mandating safer cigarettes: a hypothetical simulation of the anticipated population health gains or losses. J Policy Anal Manage. 2004;23(4):857-872. doi:10.1002/pam.20051.
123. Tengs TO, Ahmad S, Savage JM, Moore R, Gage E. The AMA proposal to mandate nicotine reduction in cigarettes: a simulation of the population health impacts. Prev Med. 2005;40(2):170-180. doi:10.1016/j. ypmed.2004.05.017.
124. Tobias MI, Cavana RY, Bloomfield A. Application of a system dynamics model to inform investment in smoking cessation services in New Zealand. Am J Public Health. 2010;100(7):1274-1281. doi:10.2105/AJPH.2009.171165.
125. Tosteson AN, Weinstein MC, Williams LW, Goldman L. Long-term impact of smoking cessation on the incidence of coronary heart disease. Am J Public Health. 1990;80(12):1481-1486. www.ncbi.nlm.nih.gov/pubmed/2240335. Accessed February 24, 2015.
126. Townsend J. Policies to halve smoking deaths. Addiction. 1993;88(1):37-46. www.ncbi.nlm.nih.gov/pubmed/8448515. Accessed February 24, 2015.
127. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 1991;83(4):1194-1201. www.ncbi.nlm.nih.gov/pubmed/2013141. Accessed Feburary 24, 2015.
128. West R, Stapleton J. Clinical and public health significance of treatments to aid smoking cessation. Eur Respir Rev. 2008;17(110):199-204.
129. Yamaguchi N, Mizuno S, Akiba S, Sobue T, Watanabe S. A 50-year projection of lung cancer deaths among Japanese males and potential impact evaluation of anti-smoking measures and screening using a computerized simulation model. Jpn J Cancer Res. 1992;83(3):251-257. www.ncbi.nlm.nih.gov/pubmed/1582887. Accessed February 24, 2015.
130. Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: an approach to lung cancer. Cancer Causes Control. 1991;2(3):147-155. www.ncbi.nlm.nih.gov/pubmed/1873444. Accessed February 24, 2015.
131. Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: methodological issues. Environ Health Perspect. 1994;102(Suppl 8):67-71. www.ncbi.nlm.nih.gov/pubmed/7851335. Accessed February 24, 2015.
132. Ahmad S. The cost-effectiveness of raising the legal smoking age in California. Med Decis Making. 2005;25(3):330-340. doi:10.1177/027 2989X05276859.
133. Ahmad S. Closing the youth access gap: the projected health benefits and cost savings of a national policy to raise the legal smoking age to 21 in the United States. Health Policy. 2005;75(1):74-84. doi:10.1016/j. healthpol.2005.02.004.
134. Ahmad S. Increasing excise taxes on cigarettes in California: a dynamic simulation of health and economic impacts. Prev Med. 2005;41(1):276-283. doi:10.1016/j.ypmed.2004.10.024.
135. Ahmad S, Franz GA. Raising taxes to reduce smoking prevalence in the US: a simulation of the anticipated health and economic impacts. Public Health. 2008;122(1):3-10. doi:10.1016/j.puhe.2007.02.020.
136. Akehurst RL, Piercy J. Cost-effectiveness of the use of transdermal Nicorette patches relative to GP counselling and nicotine gum in the prevention of smoking-related diseases. Brit J Med Econ. 1994;7(1):115-122.
137. Akehurst RL, Piercy J. Cost-effectivenss of the use of Nicorette nasal spray to assist quitting smoking among heavy smokers. Brit J Med Econ. 1994;7(2):155-184.
138. Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig. 2009;29(10):655-665. doi:10.2165/11317730-000000000-00000.
139. Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece. Clin Ther. 2012;34(8):1803-1814. doi:10.1016/j.clinthera.2012.07.002.
140. Athanasakis K, Souliotis K, Tountas Y, Kyriopoulos J, Hatzakis A. A cost-utility analysis of hypertension treatment in Greece: assessing the impact of age, sex and smoking status, on outcomes. J Hypertens. 2012;30(1):227-234. doi:10.1097/HJH.0b013e32834d9f18.
141. Bae JY, Kim CH, Lee EK. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. Value Health. 2009;12(Suppl 3):S70-S73. doi:10.1111/j.1524-4733.2009.00631.x.
142. Barnett PG, Wong W, Hall S. The cost-effectiveness of a smoking cessation program for out-patients in treatment for depression. Addiction. 2008;103(5):834-840. doi:10.1111/j.1360-0443.2008.02167.x.
143. Bauld L, Boyd KA, Briggs AH, et al. One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. Nicotine Tob Res. 2011;13(2):135-145. doi:10.1093/ntr/ntq222.
144. Baxter AP, Milner PC, Hawkins S, et al. The impact of heart health promotion on coronary heart disease lifestyle risk factors in schoolchildren: lessons learnt from a community-based project. Public Health. 1997;111(4):231-237. www.ncbi.nlm.nih.gov/pubmed/9242036. Accessed February 24, 2015.
145. Begh RA, Aveyard P, Upton P, et al. Promoting smoking cessation in Pakistani and Bangladeshi men in the UK: pilot cluster randomised controlled trial of trained community outreach workers. Trials. 2011;12:197. doi:10.1186/1745-6215-12-197.
146. Bertram MY, Lim SS, Wallace AL, Vos T. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Tob Control. 2007;16(4):255-260. doi:10.1136/tc.2006.017657.
147. Bolin K, Lindgren B, Willers S. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Chest. 2006;129(3):651-660. doi:10.1378/chest.129.3.651.
148. Bolin K, Mork AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy-cost-utility results for Sweden 2003. Respir Med. 2008;102(5):699-710. doi:10.1016/j. rmed.2007.12.018.
149. Bolin K, Mork AC, Wilson K. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract. 2009;15(3):478-485. www.ncbi.nlm.nih.gov/pubmed/19536915. Accessed February 24, 2015.
150. Bolin K, Wilson K, Benhaddi H, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation-results from four European countries. Eur J Public Health. 2009;19(6):650-654. doi:10.1093/eurpub/ckp075.
151. Boyd KA, Briggs AH. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction. 2009;104(2):317-325. doi:10.1111/j.1360-0443.2008.02449.x.
152. Brown HS III, Stigler M, Perry C, Dhavan P, Arora M, Reddy KS. The cost-effectiveness of a school-based smoking prevention program in India. Health Promot Int. 2013;28(2):178-186. doi:10.1093/heapro/dar095.
153. Caro JJ, Klittich WS, Strauss G. Could chest X-ray screening for lung cancer be cost-effective? Cancer. 2000;89(Suppl 11):2502-2505. www.ncbi.nlm.nih.gov/pubmed/11147636. Accessed February 24, 2015.
154. Chandra K, Blackhouse G, McCurdy BR, et al. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Ont Health Technol Assess Ser. 2012;12(12):1-61. www.ncbi.nlm.nih.gov/pubmed/23074422. Accessed February 24, 2015.
155. Chen PC, Lee YC, Tsai ST, Lai CK. A cost-benefit analysis of the outpatient smoking cessation services in Taiwan from a societal viewpoint. Nicotine Tob Res. 2012;14(5):522-530. doi:10.1093/ntr/ntr241.
156. Chevreul K, Cadier B, Durand-Zaleski I, Chan E, Thomas D. Cost effectiveness of full coverage of the medical management of smoking cessation in France. Tob Control. 2014;23(3):223-230. doi:10.1136/tobaccocontrol-2012-050520.
157. Chirikos TN, Herzog TA, Meade CD, Webb MS, Brandon TH. Costeffectiveness analysis of a complementary health intervention: the case of smoking relapse prevention. Int J Technol Assess Health Care. 2004;20(4):475-480. www.ncbi.nlm.nih.gov/pubmed/15609798. Accessed February 24, 2015.
158. Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control. 2006;15(3):152-159. doi:10.1136/tc.2005.011551.
159. Crealey GE, McElnay JC, Maguire TA, O'Neill C. Costs and effects associated with a community pharmacy-based smoking-cessation programme. Pharmacoeconomics. 1998;14(3):323-333. www.ncbi.nlm.nih.gov/pubmed/10186470. Accessed February 24, 2015.
160. Croghan IT, Offord KP, Evans RW, et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc. 1997;72(10):917-924. doi:10.1016/S0025-6196(11)63361-2.
161. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Costeffectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278(21):1759-1766. www.ncbi.nlm.nih.gov/pubmed/9388153. Accessed February 24, 2015.
162. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA. 1989;261(1):75-79. www.ncbi.nlm.nih.gov/pubmed/2491762. Accessed February 24, 2015.
163. DiFranza JR, Peck RM, Radecki TE, Savageau JA. What is the potential cost-effectiveness of enforcing a prohibition on the sale of tobacco to minors? Prev Med. 2001;32(2):168-174. doi:10.1006/pmed.2000.0795.
164. Dino G, Horn K, Abdulkadri A, Kalsekar I, Branstetter S. Costeffectiveness analysis of the Not On Tobacco program for adolescent smoking cessation. Prev Sci. 2008;9(1):38-46. doi:10.1007/s11121-008-0082-0.
165. Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India's 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health. 2011;8(5):1271-1286. doi:10.3390/ijerph8051271.
166. Eddy DM, Peskin B, Shcheprov A, Pawlson G, Shih S, Schaaf D. Effect of smoking cessation advice on cardiovascular disease. Am J Med Qual. 2009;24(3):241-249. doi:10.1177/1062860609332509.
167. Emery S, Choi WS, Pierce JP. The social costs of tobacco advertising and promotions. Nicotine Tob Res. 1999;1(Suppl 2):S83-91. www.ncbi.nlm.nih.gov/pubmed/11768191. Accessed February 24, 2015.
168. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Mölken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health. 2005;8(3):178-190. doi:10.1111/j.1524-4733.2005.04008.x.
169. Fellows JL, Bush T, McAfee T, Dickerson J. Cost effectiveness of the Oregon quitline "free patch initiative". Tob Control. 2007;16(Suppl 1):i47-52. doi:10.1136/tc.2007.019943.
170. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996;275(16):1247-1251. www.ncbi.nlm.nih.gov/pubmed/8601956. Accessed February 24, 2015.
171. Fishman PA, Ebel BE, Garrison MM, Christakis DA, Wiehe SE, Rivara FP. Cigarette tax increase and media campaign cost of reducing smoking-related deaths. Am J Prev Med. 2005;29(1):19-26. doi:10.1016/j.amepre.2005.03.004.
172. Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care. 2007;23(1):71-79. doi:10.1017/S0266462307051598.
173. Gartner CE, Barendregt JJ, Wallace A, Hall WD. Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents? Addiction. 2012;107(4):801-809. doi:10.1111/j.1360-0443.2011.03718.x.
174. Gilbert AR, Pinget C, Bovet P, Cornuz J, Shamlaye C, Paccaud F. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. Tob Control. 2004;13(2):190-195. www.ncbi.nlm.nih.gov/pubmed/15175539. Accessed February 24, 2015.
175. Godfrey C, Parrott S, Coleman T, Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction. 2005;100(Suppl 2):70-83. www.ncbi.nlm.nih.gov/pubmed/15844290. Accessed February 24, 2015.s
176. Goldman D, Cutler DM, Shang B, Joyce GF. The value of elderly disease prevention. Forum Health Econ Policy. 2006;9(2).
177. Gordon LG, Hirst NG, Young RP, Brown PM. Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness? Cost EffResour Alloc. 2010;8:18. doi:10.1186/1478-7547-8-18.
178. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. Eur J Health Econ. 2013;14(5):789-797. doi:10.1007/s10198-012-0424-5.
179. Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plan. 2011;26(3):210-222. doi:10.1093/heapol/czq045.
180. Halpern MT, Dirani R, Schmier JK. The cost effectiveness of varenicline for smoking cessation. Manag Care Interface. 2007;20(10):18-25. www.ncbi.nlm.nih.gov/pubmed/18405203. Accessed February 24, 2015.
181. Halpern MT, Dirani R, Schmier JK. Impacts of a smoking cessation benefit among employed populations. J Occup Environ Med. 2007;49(1):11-21. doi:10.1097/JOM.0b013e31802db579.
182. Halpern MT, Khan ZM, Young TL, Battista C. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm. 2000;57(15):1421-1429. www.ncbi.nlm.nih.gov/pubmed/10938982. Accessed February 24, 2015.
183. Hettle R, Wilson N, Peter T, Ezernieks J, Hackl D, Wolf C. Costeffectiveness of varenicline compared to placebo as an aid to smoking cessation in patients with cardiovascular disease. The Open Pharmacoeconomics & Health Economics Journal. 2012;4:8-17.
184. Higashi H, Barendregt JJ. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support. Addiction. 2012;107(3):658-670. doi:10.1111/j.1360-0443.2011.03632.x.
185. Higashi H, Truong KD, Barendregt JJ, et al. Cost effectiveness of tobacco control policies in Vietnam: the case of population-level interventions. Appl Health Econ Health Policy. 2011;9(3):183-196. doi:10.2165/11539640-000000000-00000.
186. Højgaard B, Olsen KR, Pisinger C, Tønnesen H, Gyrd-Hansen D. The potential of smoking cessation programmes and a smoking ban in public places: comparing gain in life expectancy and cost effectiveness. Scand J Public Health. 2011;39(8):785-796. doi:10.1177/1403494811421416.
187. Holtgrave DR, Wunderink KA, Vallone DM, Healton CG. Costutility analysis of the National truth campaign to prevent youth smoking. Am J Prev Med. 2009;36(5):385-388. doi:10.1016/j. amepre.2009.01.020.
188. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Mölken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010;65(8):711-718. doi:10.1136/thx.2009.131631.
189. Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J. 2005;26(2):223-233. doi:10.1183/09031936.05.00122004.
190. Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24(1):51-61. doi:10.1185/030079908X242917.
191. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497-511. www.ncbi.nlm.nih.gov/pubmed/18489200. Accessed February 24, 2015.
192. Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control. 2008;17(6):379-384. doi:10.1136/tc.2008.025213.
193. Igarashi A, Takuma H, Fukuda T, Tsutani K. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics. 2009;27(3):247-261. doi:10.2165/00019053-200927030-00007.
194. Javitz HS, Swan GE, Zbikowski SM, et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care. 2004;10(3):217-226. www.ncbi.nlm.nih.gov/pubmed/15032259. Accessed February 24, 2015.
195. Javitz HS, Zbikowski SM, Deprey M, et al. Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation. Transl Behav Med. 2011;1(1):182-190. doi:10.1007/s13142-010-0009-8.
196. Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health. 2005;33(5):343-352. www.ncbi.nlm.nih.gov/pubmed/16265801. Accessed February 24, 2015.
197. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118(5):576-585. doi:10.1161/CIRCULATIONAHA.108.190186.
198. Kaper J, Wagena EJ, van Schayck CP, Severens JL. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmacoeconomics. 2006;24(5):453-464. www.ncbi.nlm.nih.gov/pubmed/16706571. Accessed February 24, 2015.
199. Keeler TE, Hu TW, Keith A, et al. The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ. 2002;11(5):389-402. doi:10.1002/hec.677.
200. Knight C, Howard P, Baker CL, Marton JP. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010;13(2):209-214. doi:10.1111/j.1524-4733.2009.00672.x.
201. Knight C, Marbaix S, Annemans L, Prignot J, Bowrin K. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective. Acta Clin Belg. 2012;67(6):416-422. doi:10.2143/ACB.67.6.2062706.
202. Kotz D, Stapleton JA, Owen L, West R. How cost-effective is 'No Smoking Day'? Tob Control. 2011;20(4):302-304. doi:10.1136/tc.2009.034397.
203. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Costeffectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol. 1993;22(6):1697-1702. www.ncbi.nlm.nih.gov/pubmed/8227841. Accessed February 24, 2015.
204. Ladapo JA, Jaffer FA, Weinstein MC, Froelicher ES. Projected costeffectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. Arch Intern Med. 2011;171(1):39-45. doi:10.1001/archinternmed.2010.479.
205. Lai T, Habicht J, Reinap M, Chisholm D, Baltussen R. Costs, health effects and cost-effectiveness of alcohol and tobacco control strategies in Estonia. Health Policy. 2007;84(1):75-88. doi:10.1016/j. healthpol.2007.02.012.
206. Lal A, Mihalopoulos C, Wallace A, Vos T. The cost-effectiveness of callback counselling for smoking cessation. Tob Control. 2014;23(5):437-442. doi:10.1136/tobaccocontrol-2012-050907.
207. Leutzinger JA, Ozminkowski RJ, Dunn RL, et al. Projecting future medical care costs using four scenarios of lifestyle risk rates. Am J Health Promot. 2000;15(1):35-44. www.ncbi.nlm.nih.gov/pubmed/11184117. Accessed February 24, 2015.
208. Levy DE. Employer-sponsored insurance coverage of smoking cessation treatments. Am J Manag Care. 2006;12(9):553-562. www.ncbi.nlm.nih.gov/pubmed/16961444. Accessed February 24, 2015.
209. Levy DT, Friend K. A simulation model of policies directed at treating tobacco use and dependence. Med Decis Making. 2002;22(1):6-17. www.ncbi.nlm.nih.gov/pubmed/11833665. Accessed February 24, 2015.
210. Lightwood JM, Phibbs CS, Glantz SA. Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics. 1999;104(6):1312-1320. www.ncbi.nlm.nih.gov/pubmed/10585982. Accessed February 24, 2015.
211. Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin. 2010;26(3):549-560. doi:10.1185/03007990903542666.
212. Lock K, Wilson K, Murphy D, Riesco JA. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2011;12(17):2613-2626. doi:10.1517/146 56566.2011.628935.
213. Löfroth E, Lindholm L, Wilhelmsen L, Rosén M. Optimising health care within given budgets: primary prevention of cardiovascular disease in different regions of Sweden. Health Policy. 2006;75(2):214-229. doi:10.1016/j.healthpol.2005.03.008.
214. Lutz MA, Lovato P, Cuesta G. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. Hosp Pract (1995). 2012;40(1):24-34. doi:10.3810/hp.2012.02.945.
215. Lutz MA, Lovato P, Cuesta G. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua. Hosp Pract (1995). 2012;40(1):35-43. doi:10.3810/hp.2012.02.946.
216. Mani K, Wanhainen A, Lundkvist J, Lindström D. Cost-effectiveness of intensive smoking cessation therapy among patients with small abdominal aortic aneurysms. J Vasc Surg. 2011;54(3):628-636. doi:10.1016/j. jvs.2011.02.055.
217. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6(11):1841-1848. doi:10.1097/JTO.0b013e31822e59b3.
218. Meenan RT, Stevens VJ, Hornbrook MC, et al. Cost-effectiveness of a hospital-based smoking cessation intervention. Med Care. 1998;36(5):670-678. www.ncbi.nlm.nih.gov/pubmed/9596058. Accessed February 24, 2015.
219. Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30(9):825-840. doi:10.2165/11591340-000000000-00000.
220. Miller LS, Max W, Sung HY, Rice D, Zaretsky M. Evaluation of the economic impact of California's Tobacco Control Program: a dynamic model approach. Tob Control. 2010;19(Suppl 1):i68-76. doi:10.1136/tc.2008.029421.
221. Najafzadeh M, Marra CA, Lynd LD, et al. Future impact of various interventions on the burden of COPD in Canada: a dynamic population model. PLoS One. 2012;7(10):e46746. doi:10.1371/journal. pone.0046746.
222. Neyt M, De Laet C, Van Brabandt H, Franco O, Ramaekers D. Costeffectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. ActaCardiol. 2009;64(1):1-10. www.ncbi.nlm.nih.gov/pubmed/19317290. Accessed February 24, 2015.
223. Nohlert E, Helgason AR, Tillgren P, Tegelberg A, Johansson P. Comparison of the cost-effectiveness of a high-and a low-intensity smoking cessation intervention in Sweden: a randomized trial. Nicotine Tob Res. 2013;15(9):1519-1527. doi:10.1093/ntr/ntt009.
224. Nohlert E, Öhrvik J, Tegelberg Å, Tillgren P, Helgason ÁR. Long-term follow-up of a high-and a low-intensity smoking cessation intervention in a dental setting-a randomized trial. BMC Public Health. 2013;13:592. doi:10.1186/1471-2458-13-592.
225. Oh JK, Lim MK, Yun EH, Shin SH, Park EY, Park EC. Cost and effectiveness of the nationwide government-supported Smoking Cessation Clinics in the Republic of Korea. Tob Control. 2013;22(e1):e73-e77. doi:10.1136/tobaccocontrol-2011-050110.
226. Olsen KR, Bilde L, Juhl HH, et al. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ. 2006;7(4):255-264. doi:10.1007/s10198-006-0362-1.
227. Ong MK, Glantz SA. Cardiovascular health and economic effects of smoke-free workplaces. Am J Med. 2004;117(1):32-38. doi:10.1016/j. amjmed.2004.02.029.
228. Ong MK, Glantz SA. Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison. Am J Public Health. 2005;95(6):969-975. doi:10.2105/AJPH.2004.040667.
229. Orme ME, Hogue SL, Kennedy LM, Paine AC, Godfrey C. Development of the health and economic consequences of smoking interactive model. Tob Control. 2001;10(1):55-61. www.ncbi.nlm.nih.gov/pubmed/11226362. Accessed February 24, 2015.
230. Ortegón M, Lim S, Chisholm D, Mendis S. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e607. doi:10.1136/bmj.e607.
231. Oster G, Huse DM, Delea TE, Colditz GA. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA. 1986;256(10):1315-1318. www.ncbi.nlm.nih.gov/pubmed/3091857. Accessed February 24, 2015.
232. Paradis PE, Mishagina N, Carter V, Raymond V. Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment. Healthc Q. 2012;15(2):52-60. www.ncbi.nlm.nih.gov/pubmed/22688206. Accessed February 24, 2015.
233. Pinget C, Martin E, Wasserfallen JB, Humair JP, Cornuz J. Costeffectiveness analysis of a European primary-care physician training in smoking cessation counseling. Eur J Cardiovasc Prev Rehabil. 2007;14(3):451-455. doi:10.1097/HJR.0b013e32804955a0.
234. Plans-Rubio P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain. Pharmacoeconomics. 1998;13(5, pt 2):623-643. www.ncbi.nlm.nih.gov/pubmed/17165328. Accessed February 24, 2015.
235. Plans-Rubio P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care. 1998;14(2):320-330. www.ncbi.nlm.nih.gov/pubmed/9611906. Accessed February 24, 2015.
236. Prathiba BV, Tjeder S, Phillips C, Campbell IA. A smoking cessation counsellor: should every hospital have one? J R Soc Promot Health. 1998;118(6):356-359. www.ncbi.nlm.nih.gov/pubmed/10076697. Accessed February 24, 2015.
237. Quist-Paulsen P, Lydersen S, Bakke PS, Gallefoss F. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2006;13(2):274-280. doi:10.1097/01.hjr.0000192742.81231.91.
238. Ranson MK, Jha P, Chaloupka FJ, Nguyen SN. Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies. Nicotine Tob Res. 2002;4(3):311-319. doi:10.1080/14622200210141000.
239. Ratcliffe J, Cairns J, Platt S. Cost effectiveness of a mass media-led antismoking campaign in Scotland. Tob Control. 1997;6(2):104-110. www.ncbi.nlm.nih.gov/pubmed/9291218. Accessed February 24, 2015.
240. Rubinstein A, García Martí S, Souto A, Ferrante D, Augustovski F. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost EffResour Alloc. 2009;7:10. doi:10.1186/1478-7547-7-10.
241. Ruger JP, Weinstein MC, Hammond SK, Kearney MH, Emmons KM. Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value Health. 2008;11(2):191-198. doi:10.1111/j.1524-4733.2007.00240.x.
242. Secker-Walker RH, Holland RR, Lloyd CM, Pelkey D, Flynn BS. Cost effectiveness of a community based research project to help women quit smoking. Tob Control. 2005;14(1):37-42. doi:10.1136/tc.2003.005470.
243. Secker-Walker RH, Worden JK, Holland RR, Flynn BS, Detsky AS. A mass media programme to prevent smoking among adolescents: costs and cost effectiveness. Tob Control. 1997;6(3):207-212. www.ncbi.nlm.nih.gov/pubmed/9396105. Accessed February 24, 2015.
244. Shi L, van Meijgaard J, Fielding JE. Long-term effects of health factor modification in Milwaukee County. J Public Health Manag Pract. 2013;19(2):133-138. doi:10.1097/PHH.0b013e31825490cd.
245. Simpson SA, Nonnemaker JM. New York tobacco control program cessation assistance: costs, benefits, and effectiveness. Int J Environ Res Public Health. 2013;10(3):1037-1047. doi:10.3390/ijerph10031037.
246. Slatore CG, Au DH, Hollingworth W. Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer. J Thorac Oncol. 2009;4(4):499-504. doi:10.1097/JTO.0b013e318195e23a.
247. Smit ES, Evers SM, de Vries H, Hoving C. Cost-effectiveness and costutility of Internet-based computer tailoring for smoking cessation. J Med Internet Res. 2013;15(3):e57. doi:10.2196/jmir.2059.
248. Smith MY, Cromwell J, DePue J, Spring B, Redd W, Unrod M. Determining the cost-effectiveness of a computer-based smoking cessation intervention in primary care. Manag Care. 2007;16(7):48-55. www.ncbi.nlm.nih.gov/pubmed/17907712. Accessed February 24, 2015.
249. Solberg LI, Maciosek MV, Edwards NM, Khanchandani HS, Goodman MJ. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Am J Prev Med. 2006;31(1):62-71. doi:10.1016/j.amepre.2006.03.013.
250. Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N. Costeffectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making. 2002;22(Suppl 5):S26-37. www.ncbi.nlm.nih.gov/pubmed/12369228. Accessed February 24, 2015.
251. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619-637. www.ncbi.nlm.nih.gov/pubmed/15960557. Accessed February 24, 2015.
252. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of costeffectiveness. Lancet. 1999;354(9174):210-215. www.ncbi.nlm.nih.gov/pubmed/10421303. Accessed February 24, 2015.
253. Stevens W, Thorogood M, Kayikki S. Cost-effectiveness of a community anti-smoking campaign targeted at a high risk group in London. Health Promot Int. 2002;17(1):43-50. www.ncbi.nlm.nih.gov/pubmed/11847137. Accessed February 24, 2015.
254. Swank RT, Becker DM, Jackson CA. The costs of employee smoking. A computer simulation of hospital nurses. Arch Intern Med. 1988;148(2):445-448. www.ncbi.nlm.nih.gov/pubmed/3341841. Accessed February 24, 2015.
255. Taylor M, Leonardi-Bee J, Agboola S, McNeill A, Coleman T. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction. 2011;106(10):1819-1826. doi:10.1111/j.1360-0443.2011.03493.x.
256. Tengs TO, Osgood ND, Chen LL. The cost-effectiveness of intensive national school-based anti-tobacco education: results from the tobacco policy model. Prev Med. 2001;33(6):558-570. doi:10.1006/pmed.2001.0922
257. Thavorn K, Chaiyakunapruk N. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control. 2008;17(3):177-182. doi:10.1136/tc.2007.022368.
258. Tillgren P, Rosen M, Haglund BJ, Ainetdin T, Lindholm L, Holm LE. Cost-effectiveness of a tobacco 'quit and win' contest in Sweden. Health Policy. 1993;26(1):43-53. www.ncbi.nlm.nih.gov/pubmed/10130845. Accessed February 24, 2015.
259. Tomson T, Helgason AR, Gilljam H. Quitline in smoking cessation: a cost-effectiveness analysis. Int J Technol Assess Health Care. 2004;20(4):469-474. www.ncbi.nlm.nih.gov/pubmed/15609797. Accessed February 24, 2015.
260. Tran MT, Holdford DA, Kennedy DT, Small RE. Modeling the costeffectiveness of a smoking-cessation program in a community pharmacy practice. Pharmacotherapy. 2002;22(12):1623-1631. www.ncbi.nlm.nih.gov/pubmed/12495172. Accessed February 24, 2015.
261. van Baal PH, Brouwer WB, Hoogenveen RT, Feenstra TL. Increasing tobacco taxes: a cheap tool to increase public health. Health Policy. 2007;82(2):142-152. doi:10.1016/j.healthpol.2006.09.004.
262. van Genugten ML, Hoogenveen RT, Mulder I, Smit HA, Jansen J, de Hollander AE. Future burden and costs of smoking-related disease in the Netherlands: a dynamic modeling approach. Value Health. 2003;6(4):494-499. doi:10.1046/j.1524-4733.2003.64157.x.
263. Vemer P, Rutten-van Mölken MP. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health. 2010;13(2):230-241. doi:10.1111/j.1524-4733.2009.00612.x.
264. Vemer P, Rutten-van Mölken MP, Kaper J, Hoogenveen RT, van Schayck CP, Feenstra TL. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction. 2010;105(6):1088-1097. doi:10.1111/j.1360-0443.2010.02901.x.
265. Vijgen SM, van Baal PH, Hoogenveen RT, de Wit GA, Feenstra TL. Costeffectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students. Health Educ Res. 2008;23(2):310-318. doi:10.1093/her/cym024.
266. Villanti AC, Curry LE, Richardson A, Vallone DM, Holtgrave DR. Analysis of media campaign promoting smoking cessation suggests it was cost-effective in prompting quit attempts. Health Aff(Millwood). 2012;31(12):2708-2716. doi:10.1377/hlthaff.2012.0277.
267. Wang LY, Crossett LS, Lowry R, Sussman S, Dent CW. Cost-effectiveness of a school-based tobacco-use prevention program. Arch Pediatr Adolesc Med. 2001;155(9):1043-1050. www.ncbi.nlm.nih.gov/pubmed/11529807 Accessed February 24, 2015.
268. Warner KE, Fulton GA. The economic implications of tobacco product sales in a nontobacco state. JAMA. 1994;271(10):771-776. www.ncbi.nlm.nih.gov/pubmed/8114214. Accessed February 24, 2015.
269. Warner KE, Mendez D, Smith DG. The financial implications of coverage of smoking cessation treatment by managed care organizations. Inquiry. 2004;41(1):57-69. www.ncbi.nlm.nih.gov/pubmed/15224960. Accessed February 24, 2015.
270. Warner KE, Smith RJ, Smith DG, Fries BE. Health and economic implications of a work-site smoking-cessation program: a simulation analysis. J Occup Environ Med. 1996;38(10):981-992. www.ncbi.nlm.nih.gov/pubmed/8899574. Accessed February 24, 2015.
271. Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med. 1997;26(2):264-270. doi:10.1006/pmed.1996.0127.
272. Wilson K, Hettle R, Marbaix S, et al. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. Eur J Prev Cardiol. 2012;19(5):1173-1183. doi:10.1177/1741826711420345.
273. Ye CY, Lee JM, Chen SH. Economic gains and health benefits from a new cigarette tax scheme in Taiwan: a simulation using the CGE model. BMC Public Health. 2006;6(1):62. doi:10.1186/1471-2458-6-62.
274. Levy DT, Hyland A, Higbee C, Remer L, Compton C. The role of public policies in reducing smoking prevalence in California: results from the California tobacco policy simulation model. Health Policy. 2007;82(2):167-185. doi:10.1016/j.healthpol.2006.09.008.
275. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733-743. doi:10.1177/0272989X12454579.
276. Malone RE, Warner KE. Tobacco control at twenty: reflecting on the past, considering the present and developing the new conversations for the future. Tob Control. 2012;21(2):74-76. doi:10.1136/tobaccocontrol-2012-050447.